Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

Data ReadoutpositivePasatruPositive

AI Analysis

Summary

Pasatru (garetosmab-grts) demonstrated zero new heterotopic ossification lesions in adult fibrodysplasia ossificans progressiva patients during the OPTIMA trial extension, supporting its therapeutic benefit in this rare genetic disorder.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Zero new heterotopic ossification lesions in adult FOP patients during OPTIMA trial extension

Importance:7/10

Sentiment:

0.85

FOPheterotopic ossificationPasatrugaretosmab-grtsOPTIMA trialextension studyrare disease

Related Companies

$REGN

Read the original article

Published by yahoo_finance on October 12, 2026 4:06 PM

Read Original